Back to results
US 2021/0275585 A1Published application
Compositions and methods of treating a t cell mediated disorder
AssigneeCase Western Reserve University
InventorsM. Edward Medof, Feng Lin, Michael G. Strainic
Life of this patent
Estimating the term…
Abstract
A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-β1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
Claims20
A method of treating inflammation in a subject, the method comprising:
- administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-β1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell;
- and
- administering a therapeutically effective amount of the CD4+FoxP3+ Treg cells to the subject.
A method of treating a T cell mediated disease in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of at least one complement antagonist and a pharmaceutically acceptable carrier, wherein the at least one complement antagonist substantially inhibits interaction of at least one of C3a or C5a with the C3a receptors (C3aR) and C5a receptors (C5aR) on interacting dendritic cells and CD4+T cells in the subject.
Dependencies are inferred from the claim text.